Targets › ITGAM
2 programs from 2 companies in 3 trials: 2 Phase 2, 1 Phase 1; Respiratory, Oncology; next expected readout Jul 2028.
Integrin ITGAM/ITGB2 is implicated in various adhesive interactions of monocytes, macrophages and granulocytes as well as in mediating the uptake of complement-coated particles and pathogens. It is identical with CR-3, the receptor for the iC3b fragment of the third complement component. (UniProt, P11215)
Open in Phaseline: the race on ITGAM, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| PPD Development, LP | paridiprubart CD11b/CD18 integrin antagonist | ITGAM | Phase 2 | Acute Respiratory Distress Syndrome (ARDS) | Jul 2028 |
| Fondazione Matilde Tettamanti Menotti De Marchi Onlus | CARCIK CD123/33 CAR-T cell therapy targeting CD123 and CD33 | IL3RA, ITGAM | Phase 1 | AML (Acute Myeloid Leukemia) | Oct 2028 |
Acute Respiratory Distress Syndrome (ARDS) (2) AML (Acute Myeloid Leukemia) (1)
antibody (1), small molecule (1)
PPD Development, LP (1) Fondazione Matilde Tettamanti Menotti De Marchi Onlus (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.